Zostavax Market Forecast to 2030: Analysis of Market Size, Growth Rate, Trends, and Projections

News originally published by

EIN Presswire

Zostavax Market

Zostavax Market

The Business Research Company

The Business Research Company

The Business Research Company's Zostavax Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, November 20, 2026 /EINPresswire.com/ -- "The Zostavax vaccine market is gaining attention as the need for effective shingles prevention grows worldwide. With an aging global population and expanding healthcare resources, demand for this vaccine is set to increase significantly. This overview explores the market’s size, the main factors driving its growth, and the regions leading in adoption.

Current Size and Projected Growth of the Zostavax Market
Growth during the previous years has been mainly influenced by demographic shifts toward older populations, higher rates of shingles among seniors, established immunization guidelines, the availability of live attenuated vaccines, and the wider implementation of vaccination in hospitals. Looking ahead, the market is expected to benefit from a transition to newer recombinant vaccines, rising healthcare spending on preventive measures, greater public knowledge about postherpetic neuralgia, broader adult vaccination programs, and improved vaccine distribution systems. Key trends include expanded adult immunization campaigns, increased shingles awareness, easier access to vaccines via retail pharmacies, better cold chain management, and a stronger focus on preventative healthcare initiatives.

Download a free sample of the zostavax market report:
https://thebusinessresearchcompany.com/sample_request?id=23555327&type=smp&name=Zostavax%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR

Understanding Zostavax and its Role in Shingles Prevention
Zostavax is designed to protect adults, especially those aged 50 and older, from shingles—a painful rash caused by the reactivation of the varicella-zoster virus, which originally causes chickenpox. The vaccine helps reduce the risk of shingles and complications such as postherpetic neuralgia, which can cause lasting nerve pain. Its use is a key preventive tool recommended by health authorities to protect vulnerable populations.

Healthcare Infrastructure Expansion Supporting Zostavax Market Growth
One major factor contributing to the market’s expansion is the enhancement of healthcare infrastructure in developing nations. This infrastructure encompasses the hospitals, clinics, equipment, healthcare workers, and systems needed to provide efficient medical care. Increased investments in healthcare facilities and improved service access make it easier to deliver vaccines like Zostavax to target groups through various healthcare settings such as hospitals and pharmacies. For instance, in May 2023, the UK Department of Health and Social Care reported that the government allocated over $25.33 billion (£20 billion) for the New Hospital Programme to build 40 new hospitals in England by 2030, including mental health facilities. These developments illustrate how enhanced healthcare capabilities are creating favorable conditions for vaccine distribution and administration.

View the full zostavax market report:
https://thebusinessresearchcompany.com/report/zostavax-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR

The Influence of an Aging Population on Vaccine Demand
The rising number of elderly individuals worldwide is a significant driver of Zostavax demand. People aged 65 and older often face weakened immune systems, making them more susceptible to shingles and related complications. Advances in healthcare and living standards have led to longer life expectancies, increasing this demographic segment. For example, in July 2024, the UK Parliament's House of Commons Library noted that in 2022 there were 12.7 million residents aged 65 or older in the UK—about 19% of the population—with projections rising to 22.1 million (27%) by 2072. This growing geriatric population represents a larger pool of individuals who can benefit from shingles vaccination, driving market growth.

Insurance Coverage Expansion Encourages Greater Vaccine Uptake
The expanding reach of health insurance is another important factor promoting Zostavax adoption. Insurance policies help cover the costs of medical care, and as awareness of health risks grows alongside rising healthcare expenses, more people seek financial protection. Vaccination with Zostavax reduces the likelihood of expensive treatments for shingles and its complications, making it an attractive preventive option for insurers to include in their coverage plans, especially for adults aged 50 and above. According to a June 2024 report by Health Affairs, about 92.3% of the U.S. population—approximately 316 million people—had health coverage, while 7.7%, or 26 million individuals, remained uninsured. Although the uninsured rate may rise slightly in the coming years, broad insurance coverage overall supports increased vaccine access and usage.

Regional Leadership in the Zostavax Market
In 2025, North America held the largest share of the global Zostavax market. The comprehensive market outlook also covers key regions such as Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing insight into global patterns of vaccine adoption and growth prospects.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

News From Europe!

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.